PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer
Open accessThe DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
The cyclic GMP-AMP synthase/stimulator of IFN genes (cGAS/STING) pathway detects cytosolic DNA to activate innate immune responses. Poly(ADP-ribose) polymerase inhibitors (PARPi) selectively target cancer cells with DNA repair deficiencies such as those caused by BRCA1 mutations or ERCC1 defects. Using isogenic cell lines and patient-derived samples, we showed that ERCC1-defective non-small cell lung cancer (NSCLC) cells exhibit an enhanced type I IFN transcriptomic signature and that low ERCC1 expression correlates with increased lymphocytic infiltration. We demonstrated that clinical PARPi, including olaparib and rucaparib, have cell-autonomous immunomodulatory properties in ERCC1-defective NSCLC and BRCA1-defective triple-negative breast cancer (TNBC) cells. Mechanistically, PARPi generated cytoplasmic chromatin fragments with characteristics of micronuclei; these were found to activate cGAS/STING, downstream type I IFN signaling, and CCL5 secretion. Importantly, these effects were suppressed in PARP1-null TNBC cells, suggesting that this phenotype resulted from an on-target effect of PARPi on PARP1. PARPi also potentiated IFN-γ-induced PD-L1 expression in NSCLC cell lines and in fresh patient tumor cells; this effect was enhanced in ERCC1-deficient contexts. Our data provide a preclinical rationale for using PARPi as immunomodulatory agents in appropriately molecularly selected populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“various FDA-approved and experimental PARP inhibitors have been shown to drive robust type I IFN secretion downstream of increased cytosolic availability of ssDNA or micronuclei (DNAcontaining structures generally formed by faulty mitoses) in a variety of tumors, including (but not limited to) BRCA1- and BRCA2-deficient neoplasms (Chabanon et al., 2019; Ding et al., 2018; Pantelidou et al., 2019;”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Chabanon et al., 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, the administration of PARP inhibitors has been associated with PD-L1 upregulation in various cancer cells regardless of BRCA1/2 status, presumably as a consequence of type I IFN or IFNG signaling (Chabanon et al., 2019; Jiao et al., 2017; Sen et al., 2019; Shen et al., 2019).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Chabanon et al., 2019
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · cited 2×
“While various DDR defects have been shown to critically contribute to the accumulation of mutations in the tumor genome, only some of them have proven their predictive value as biomarkers of response to anti-PD-(L)1 therapy (6, 45).”
BackgroundMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · cited 2×
“Both ERCC1 and BRCA1 defects confer sensitivity to platinum-based therapy (26, 27) and PARP inhibitors (PARPi) (28, 29), and while PARPi have demonstrated their efficacy in advanced BRCA-deficient breast cancers (30), these”
BackgroundSelf-citationPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607 · cited 1×
“Very recent impressive results of large phase III trials in NSCLC have reported unprecedented improvements in overall survival and progression free survival when using anti-programmed death receptor 1 or -ligand 1 (anti-PD-(L)1) in first-line therapy (1, 2).”
BackgroundGenetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · cited 12×
“Other DNA repair defects, such as BRCA1/2 mutations have been found enriched in ICI responders (12).”
BackgroundInfluentialGenomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448 · cited 1×
“Other DNA repair defects, such as BRCA1/2 mutations have been found enriched in ICI responders (12).”
BackgroundOlaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294 · cited 1×
“Both ERCC1 and BRCA1 defects confer sensitivity to platinum-based therapy (26, 27) and PARP inhibitors (PARPi) (28, 29), and while PARPi have demonstrated their efficacy in advanced BRCA-deficient breast cancers (30), these”
BackgroundClonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065 · cited 1×
“However, a simple correlation between DNA repair defects-induced genomic instability, TMB and response to ICI cannot be claimed (5), as tumor heterogeneity (13) and other determinants of response also play a role that, importantly, seems to be independent from TMB in response to ICI (14, 15).”
BackgroundNivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063 · cited 2×
“Very recent impressive results of large phase III trials in NSCLC have reported unprecedented improvements in overall survival and progression free survival when using anti-programmed death receptor 1 or -ligand 1 (anti-PD-(L)1) in first-line therapy (1, 2).”
Background
Research works printed but not linked: 1
- Robillard L. Preclinical evaluation of the PARP inhibitor rucaparib in combination with PD-1 PD-L1 inhibition in a syngenic BRCA2 mutant ovarian cancer model. Proceedings of the AACR. 2017;58(pt A):3650. Accessed January 7, 2019.
Cited by
Items 101–200 of 338
Woll, P. J., Gaunt, P., Danson, S. J., Steele, N. L., Ahmed, S. I., Mulatero, C., Shah, R. N. H., Bhosle, J., Hodgkinson, E., Watkins, B., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.07.007 · Cited by 46
PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review
Ratta, R., Guida, A., Scotté, F., Neuzillet, Y., Benmaziane, A., Lebrét, T., & Beuzeboc, P. (2020) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-0233-3 · Cited by 41
Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
Adashek, J. J., Jain, R., & Zhang, J. (2019) · Cells · doi:10.3390/cells8080860 · Cited by 44
“PARP inhibition has been shown to increase PD-L1 expression in DDR-mutant cancer cells [39].”
BackgroundWang, X.-D., Liu, Y.-S., Chen, M., & Hu, M.-H. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116361 · Cited by 39
McLaughlin, L. J., Stojanovic, L., Kogan, A. A., Rutherford, J. L., Choi, E. Y., Yen, R.-W. C., Xia, L., Zou, Y. S., Lapidus, R. G., Baylin, S. B., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003499117 · Cited by 41
Dealing with DNA lesions: When one cell cycle is not enough
Lezaja, A., & Altmeyer, M. (2020) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2020.11.001 · Cited by 41
Yu, J., Deng, H., & Xu, Z. (2020) · Scientific Reports · doi:10.1038/s41598-020-77800-w · Cited by 41
Nucleic Acid Immunity and DNA Damage Response: New Friends and Old Foes
Taffoni, C., Steer, A., Marines, J., Chamma, H., Vila, I. K., & Laguette, N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660560 · Cited by 45
“However, there is evidence that cGAS-STING-dependent inflammation can fuel tumorigenesis (96), promote tolerogenic responses, impair the establishment of long-term immunity (97) and lead to chemoresistance (98, 99).”
BackgroundEmerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies
Zhang, J., Yu, S., Peng, Q., Wang, P., & Fang, L. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0440 · Cited by 66
Avoid the trap: Targeting PARP1 beyond human malignancy
Kim, C., Chen, C., & Yu, Y. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.02.004 · Cited by 40
Pham, M. M., Ngoi, N. Y. L., Peng, G., Tan, D. S. P., & Yap, T. A. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.05.004 · Cited by 40
Permata, T. B. M., Sato, H., Gu, W., Kakoti, S., Uchihara, Y., YOSHIMATSU, Y., Sato, I., Kato, R., Yamauchi, M., Suzuki, K., et al. (2021) · Journal of Radiation Research · doi:10.1093/jrr/rrab050 · Cited by 38
“The cGAS/STING pathway is considered as another regulatory pathway underlying PD-L1 upregulation in response to DNA damage [26, 27].”
Xu, F., Xi, H., Liao, M., Zhang, Y., Ma, H., Wu, M., Xue, Q., Sun, H., Zhang, Y., & Xia, Y. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04386-z · Cited by 38
“Some small molecule agents may affect the immune system in cancer by regulating immune cell functions and proportion by either boosting or suppressing the antitumor responses [28, 29].”
BackgroundSaturated fatty acids dampen the immunogenicity of cancer by suppressing STING
Heath, B. R., Gong, W., Taner, H. F., Broses, L. J., Okuyama, K., Cheng, W., Jin, M., Fitzsimonds, Z. R., Manousidaki, A., Wu, Y., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112303 · Cited by 39
“54,55 External beam radiotherapy and targeted radionuclide therapy can also both activate STING-dependent IFN-I signaling to effectively prime cold cancers.”
Zhu, J., Huang, R., Yang, R., Xiao, Y., Yan, J., Zheng, C., Xiao, W., Huang, C., & Wang, Y. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02223-0 · Cited by 42
“which is likely correlated with the complex network of the tumor microenvironment (TME) [7].”
BackgroundInfluentialThe Replication Stress Response on a Narrow Path Between Genomic Instability and Inflammation
Técher, H., & Pasero, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.702584 · Cited by 41
“Thus, it has been recently shown that ERCC1deficient non-small cell lung cancer (NSCLC) cells accumulate cytosolic chromatin fragments and consecutively induce type I IFNs in response to PARP inhibition (Chabanon et al., 2019).”
BackgroundCombined strategies with PARP inhibitors for the treatment of BRCA wide type cancer
Xie, Y., Xiao, D., Li, D., Peng, M., Peng, W., Duan, H., & Yang, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1441222 · Cited by 41
Strategies involving STING pathway activation for cancer immunotherapy: Mechanism and agonists
Pan, X., Zhang, W., Guo, H., Wang, L., Wu, H., Ding, L., & Yang, B. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115596 · Cited by 37
Research Progress of PARP Inhibitor Monotherapy and Combination Therapy for Endometrial Cancer
Shen, K., Yang, L., Li, F., Zhang, F., Ding, L., Yang, J., Lu, J., Wang, N., & Wang, Y. (2021) · Current Drug Targets · doi:10.2174/1389450122666210617111304 · Cited by 34
Activation of STING in the pancreatic tumor microenvironment: A novel therapeutic opportunity
Chamma, H., Vila, I. K., Taffoni, C., Turtoï, A., & Laguette, N. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215694 · Cited by 36
Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer
Xiao, F., Wang, Z., Liu, Q., Zhang, X., Wu, N., Wang, J., & Xing, Y. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05583-z · Cited by 37
“Recent studies have revealed that PARPi can activate STING-dependent intrinsic immunity in tumor cells [97, 119].”
BackgroundCurrent and future immunotherapy approaches in ovarian cancer
Demircan, N. C., Boussios, S., Taşçı, T., & Öztürk, M. A. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-4499 · Cited by 35
“Fourth, PARPi can lead to acute inflammation, remodeling of tumor microenvironment and thus enhancement of immune response (45).”
Zhang, Y., Zhai, Q., Feng, X., Chen, D., Lu, Y., Hu, J., Xie, H., Zhou, L., Wu, J., & Zheng, S. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02519-z · Cited by 34
“Additionally, emerging evidences have revealed the antitumor roles of STING signaling within cancer cells [10, 13, 16].”
BackgroundPARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival
Shao, F., Duan, Y., Zhao, Y., Li, Y., Liu, J., Zhang, C., & He, S. (2021) · Aging · doi:10.18632/aging.202724 · Cited by 38
“Furthermore, for patients with HRD, PARPi used in the populations of ERCC1 or BRCA deficient cancers, might potentiate their therapeutic effects by regulating the signal pathway related to antitumor immunity [39, 40].”
BackgroundKhaddour, K., Maahs, L., Rodriguez, A. M. A., Maamar, Y., Samaan, S., & Ansstas, G. (2021) · Cancers · doi:10.3390/cancers13225847 · Cited by 37
cGAS in nucleus: The link between immune response and DNA damage repair
Song, J.-X., Villagomes, D., Zhao, H., & Zhu, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1076784 · Cited by 37
Zhang, N., Gao, Y., Zeng, Z., Luo, Y., Jiang, X., Zhang, J., Li, J., Zhang, J., Gong, Y. Q., & Xie, C. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02591-z · Cited by 32
“PARPi were reported to increase the levels of CCL5 [17] and IFNγ [39].”
BackgroundReplication stress: from chromatin to immunity and beyond
Lin, Y., & Pasero, P. (2021) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2021.08.004 · Cited by 33
“These include the use of ATR inhibitors in oxaliplatin-resistant colon cancer [67] and PARP inhibitors in ERCC1-deficient non-small cell lung cancer [68] to increase RS, activate the cGAS/ STING pathway and promote antitumor immunity.”
BackgroundImmunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents
Fucikova, J. P., Palová-Jelínková, L., Klapp, V., Holíček, P., Láníčková, T., Kašíková, L., Drozenová, J., Cibula, D., Álvarez-Abril, B., García-Martínez, E., et al. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.01.010 · Cited by 32
Jabbour, S. K., Cho, B. C., Bria, E., Kato, T., Bhosle, J., Gainor, J. F., Reguart, N., Wang, L., Morgensztern, D., Shentu, Y., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.04.003 · Cited by 36
“11,12 This effect potentially sensitizes tumor cells to PD-1/PD-L1 inhibitor therapy, and provides a rationale for the combination of pembrolizumab and PARP inhibition in cancer treatment.”
BackgroundDNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy
Gilmore, E. S., McCabe, N., Kennedy, R. D., & Parkes, E. E. (2019) · Journal of Oncology · doi:10.1155/2019/4325105 · Cited by 33
Kwok, M., Agathanggelou, A., & Stanković, T. (2024) · Blood · doi:10.1182/blood.2023019963 · Cited by 32
Labrie, M., Li, A., Creason, A., Betts, C. B., Keck, J. M., Johnson, B., Sivagnanam, S., Boniface, C. T., Ma, H., Blucher, A., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00232-w · Cited by 32
Wu, K., Liang, J., Shao, Y., Xiong, S.-C., Feng, S., & Li, X. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.777663 · Cited by 34
“As for PARP inhibitor combined immunotherapy, a recent study found that PARP inhibitor could increase the expression of programmed death ligand 1 (PD-L1) in DDR-mutated cells and facilitate the release of neoantigens due to DNA damage in tumors (Chabanon et al., 2019).”
BackgroundXu, Y., Nowsheen, S., & Deng, M. (2023) · Cancers · doi:10.3390/cancers15051619 · Cited by 33
“PARP inhibitors (PARPi) have been shown to potentiate IFN-γ-induced PDL1 expression in NSCLC cell lines and pancreatic cancer [177,178].”
BackgroundGenomic Features of Response to Combination Immunotherapy in Lung Cancer
Früh, M., & Peters, S. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.005 · Cited by 31
Bound, N. T., Vandenberg, C. J., Kartikasari, A. E. R., Plebanski, M., & Scott, C. L. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.886170 · Cited by 34
“Upregulation of PD-L1 expression can occur through several mechanisms including PD-L1 promotor binding by NF-kB, JAK1/2 activation and IFNy secretion following type I IFN response (Bellucci et al., Frontiers in Genetics frontiersin.org10 2015; Chabanon et al., 2019; Cai et al., 2020).”
BackgroundAdvances and challenges in immunotherapy of small cell lung cancer
Guo, H., Li, L., & Cui, J. (2020) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2020.01.13 · Cited by 32
“By inhibiting DNA repair and promoting apoptosis of tumor cells, PARP inhibitors can enhance the efficacy of radiotherapy, alkalinizing agents and platinum drug chemotherapy (84).”
BackgroundKorneenko, T. V., Pestov, N. B., Nevzorov, I. A., Daks, A. A., Николаевич, Т. К., Солопова, О. Н., & Barlev, N. A. (2023) · Pharmaceuticals · doi:10.3390/ph16121675 · Cited by 30
Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial
Remón, J., Besse, B., Leary, A. F., Bièche, I., Job, B., Lacroix, L., Auguste, A., Mauduit, M., Audigier-Valette, C., Raimbourg, J., et al. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100068 · Cited by 36
“Indeed, preclinical models have provided the rationale for a potential synergism with a combination of a PARP inhibitor and ICIs in NSCLC.(40) Several clinical trials are currently assessing this combination in patients with NSCLC (NCT03308942 in first line, NCT02484404 in previously treated, and ORION trial NCT037754…”
BackgroundInfluentialSelf-citationWayne, J., Brooks, T., Landras, A., & Massey, A. J. (2021) · FEBS Journal · doi:10.1111/febs.15747 · Cited by 29
PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?
Chan, W. Y., Brown, L. J., Reid, L., & Joshua, A. M. (2021) · Cancers · doi:10.3390/cancers13184520 · Cited by 31
“Therefore, better understanding of the determinants of response to ICIs and identification of combinations that would increase the proportion of patients benefiting from these therapies are crucial [42].”
BackgroundSaha, A., Zhao, S., Kindall, A., Wilder, C. S., Friedman, C. A., Clark, R., Georgiou, G., Stone, E. M., Kidane, D., & DiGiovanni, J. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02677-2 · Cited by 30
“Likewise, preclinical studies have shown that DNA damaging chemotherapy treatment enhances PCa response to immunotherapy [48] and in particular, Olaparib administration upregulates PD-L1 expression in other tumor models [49, 50].”
BackgroundThe Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma
Fiste, O., Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., Liontos, M., Koutsoukos, K., Dimopoulos, M. A., & Zagouri, F. (2021) · Vaccines · doi:10.3390/vaccines9050422 · Cited by 29
Gao, Y., Feng, C., Ma, J., & Yan, Q. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116048 · Cited by 28
Immune Modulation in Lung Cancer: Current Concepts and Future Strategies
Gaissmaier, L., & Christopoulos, P. (2020) · Respiration · doi:10.1159/000510385 · Cited by 30
Impact of DNA damage response defects in cancer cells on response to immunotherapy and radiotherapy
Czajkowski, D., Szmyd, R., & Gee, H. E. (2022) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.13413 · Cited by 29
“Combination of PARPi with anti-PD-(L)1 inhibitors in ERCC1-deficient NSCLC patients resulted in cell-autonomous and constitutive increase in STING expression and IFN-1 signalling in vitro, as well as increased intratumoural lymphocytic infiltration in vivo.(165) Another series reported that coupling of PDL1 blockade w…”
BackgroundTargeting ATR Pathway in Solid Tumors: Evidence of Improving Therapeutic Outcomes
Mavroeidi, D., Georganta, A., Panagiotou, Ε., Syrigos, K., & Souliotis, V. L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052767 · Cited by 27
“The activation of cGAS/STING inflammatory responses following PARP [78] or ATR [79] inhibition may also induce the formation of micronuclei capable of activating innate immune responses [58,80].”
BackgroundLampert, E. J., Cimino‐Mathews, A., Lee, J. S., Nair, J. R., Lee, M.-J., Yuno, A., An, D., Trepel, J. B., Ruppin, E., & Lee, J.-M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000516 · Cited by 27
Beyond DNA repair: the novel immunological potential of PARP inhibitors
Chabanon, R. M., Soria, J., Lord, C. J., & Postel-Vinay, S. C. (2019) · Molecular & Cellular Oncology · doi:10.1080/23723556.2019.1585170 · Cited by 30
“In this latter area, several lines of evidence now support that specific DNA repair defects in tumor cells can activate, in a cell-autonomous fashion, the innate immune system via the cyclic GMP-AMP synthase/ stimulator of interferon genes (cGAS/STING) pathway.(6,7) In”
Self-citationCampillo‐Marcos, I., Monte-Serrano, E., Navarro-Carrasco, E., García-González, R., & Lazo, P. A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.715126 · Cited by 25
“In this context, chaetocin also induces cell death in different types of tumors, including multiple myeloma (Isham et al., 2007), leukemia (Chaib et al., 2012), melanoma (Han et al., 2017), gliomas (Dixit et al., 2014; Ozyerli-Goknar et al., 2019), and gastric (Liao et al., 2019), ovarian (Li et…”
BackgroundDalmasso, B., Puccini, A., Catalano, F., Borea, R., Iaia, M. L., Bruno, W., Fornarini, G., Sciallero, S., Rebuzzi, S. E., & Ghiorzo, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094709 · Cited by 28
“PARP-i plus Immunotherapy PARP-i have shown to have an immunomodulatory effect modulating the tumor immune microenvironment by a wide range of molecular and cellular mechanisms, such as increasing genomic instability, activating immune pathways and increasing PD-L1 expression on cancer cells, which might promote respo…”
BackgroundInfluentialOpinion: PARP inhibitors in cancer—what do we still need to know?
Wicks, A. J., Krastev, D. B., Pettitt, S. J., Tutt, A. N. J., & Lord, C. J. (2022) · Open Biology · doi:10.1098/rsob.220118 · Cited by 27
Self-citationImmunotherapy in Prostate Cancer: State of Art and New Therapeutic Perspectives
Maselli, F. M., Giuliani, F., Laface, C., Perrone, M., Melaccio, A., Santis, P. D., Santoro, A. N., Guarini, C., Iaia, M. L., & Fedele, P. (2023) · Current Oncology · doi:10.3390/curroncol30060432 · Cited by 28
The multiple faces of cGAS-STING in antitumor immunity: prospects and challenges
Zhou, Z., Huang, S., Fan, F., Xu, Y., Moore, C., Li, S., & Han, C. (2024) · Medical Review · doi:10.1515/mr-2023-0061 · Cited by 26
“Even though some previous studies reported that antitumor treatments could induce the slight increase of tumor-derived IFN-I and provoke the antitumor e ff ect in a tumor-intrinsic cGAS-STING dependent manner [46, 84, 129 – 131].”
BackgroundResultXie, Y., Liu, Y., Lin, M., Li, Z., Shen, Z., Yin, S., Zheng, Y., Zou, Y., Zhang, Y., Zhan, Y., et al. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.12.023 · Cited by 24
The activation of cGAS-STING pathway offers novel therapeutic opportunities in cancers
Wang, Y., Zhu, Y., Cao, Y., Li, Y., Zhang, Z., Fleishman, J. S., Cheng, S., Chen, J., & Ding, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1579832 · Cited by 43
PARP inhibitors in small cell lung cancer: The underlying mechanisms and clinical implications
Wang, X., Zeng, X., Li, D., Zhu, C., Guo, X., Feng, L., & Yu, Z. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113458 · Cited by 29
Sobczak, M., Zyma, M., & Robaszkiewicz, A. (2020) · Cells · doi:10.3390/cells9092040 · Cited by 28
Role of STING in the treatment of non-small cell lung cancer
Tang, W., Zhou, W., Ji, M., & Yang, X. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01586-x · Cited by 26
“Research has validated that PARPI can selectively target cancer cells with DNA repair defects, including those resulting from BRCA1 mutations or excision repair cross-complementing group 1 (ERCC1) defects [48].”
BackgroundSynergistic targeting strategies for prostate cancer
Li, X., Han, Z., & Ai, J. (2025) · Nature Reviews Urology · doi:10.1038/s41585-025-01042-6 · Cited by 27
“…the activity and recruitment of immunosuppressive cells such as MDSCs, T reg cells and TAMs are inhibited through drug regulation 351 ; fourth, ICIs such as PDL1 are upregulated when immune-related signalling is activated by drug molecules, which might enhance the effect of ICB therapy 17,352 .”
Dong, Q., Yu, T., Chen, B., Liu, M., Sun, X., Cao, H., Liu, K., Xu, H., Wang, Y., Zhuang, S., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.165268 · Cited by 23
Delving into PARP inhibition from bench to bedside and back
Grignani, G., Merlini, A., Sangiolo, D., D’Ambrosio, L., & Pignochino, Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107446 · Cited by 23
Timilsina, S., Huang, J. Y., Abdelfattah, N., Medina, D., Singh, D., Abdulsahib, S. M., Subbarayalu, P., Do, T. P., Venkata, P. P., Nirzhor, S. S. R., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59186-3 · Cited by 26
Wang, Z., Wang, Y., He, Z., & Liu, C. (2025) · Advanced Science · doi:10.1002/advs.202509890 · Cited by 25
LeVee, A. A., Lin, C. Y., Posadas, E. M., Figlin, R. A., Bhowmick, N. A., Vizio, D. D., Ellis, L., Rosser, C. J., Freeman, M. R., Theodorescu, D., et al. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s315170 · Cited by 22
Pharmacological boosting of cGAS activation sensitizes chemotherapy by enhancing antitumor immunity
Liu, H., Su, H., Wang, F., Dang, Y., Ren, Y., Yin, S., Lu, H., Zhang, H., Wu, J., Xu, Z., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112275 · Cited by 21
Ma, X., Chen, M.-M., & Meng, L. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01210-7 · Cited by 25
“Chemotherapies (e.g. cisplatin [116, 117], paclitaxel [118], doxorubicin [119]), radiotherapies [68], and therapies that target DNA damage response (e.g., PARP inhibitors [19, 120]) have been shown to activate cGAS-mediated production of cGAMP by promoting micronuclei or chromatin bridge formation.”
Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a review
Mao, X., Lee, N. K., Saad, S. E., & Fong, I. L. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-742 · Cited by 24
“Pre-clinical trial demonstrated PARP inhibitor potentiated IFN-γ -induced PD-L1 expression in NSCLC cell lines, enhanced in ERCC1-deficient contexts, promoted cellular immune response (146).”
BackgroundWhen DNA damage responses meet tumor immunity: From mechanism to therapeutic opportunity
Pan, D., Wang, Q., Shen, A., Qi, Z., Zheng, C., & Hu, B. (2024) · International Journal of Cancer · doi:10.1002/ijc.34954 · Cited by 22
“52,109 Combining PARPi with other ICIs, such as CTLA-4 antibodies, yields similar effects.”
BackgroundPromising Combinatorial Therapeutic Strategies against Non-Small Cell Lung Cancer
Kaur, P., Singh, S. K., Mishra, M. K., Singh, S., & Singh, R. (2024) · Cancers · doi:10.3390/cancers16122205 · Cited by 27
Nanoparticle-Based Strategies to Enhance the Efficacy of STING Activators in Cancer Immunotherapy
Qiao, Y., Wei, L., Su, Y., Tan, Q., Yang, X., & Li, S. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s515893 · Cited by 21
“80,103 Furthermore, the CHK1 inhibitor prexasertib accelerates DNA double-strand breaks and STING activation, subsequently enhancing T-cell recruitment and effector cell function in small cell lung cancer (SCLC) mouse models.”
Yi, X.-F., Gao, R.-L., Sun, L., Wu, Z.-X., Zhang, S., Huang, L., Han, C., & Ma, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114770 · Cited by 25
Li, P., Du, Y., Qiu, J., Li, D., Li, G., & Shan, G. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301517 · Cited by 21
Vasiyani, H., & Wadhwa, B. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111647 · Cited by 21
Immunomodulatory roles of PARPs: Shaping the tumor microenvironment, one ADP-ribose at a time
Brooks, D. M., Anand, S., & Cohen, M. S. (2023) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2023.102402 · Cited by 20
Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma
Phillipps, J., Nassief, G., Morecroft, R., Adeyelu, T. T., Elliott, A., Abdulla, F. R., Vanderwalde, A. M., Park, S., Butt, O. H., Zhou, A. Y., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00684-w · Cited by 19
“In addition, PARPi were found to increase cell-Fig intrinsic immunity by creating cytoplasmic chromatin fragments that further activate the cGAS/STING pathway, increase cytokine production, and activate downstream IFN signaling in DNA damage response-de fi cient tumor cells 34 .”
BackgroundImmunology and Immune Checkpoint Inhibition in Ovarian Cancer – Current Aspects
Bronger, H. (2021) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1475-4335 · Cited by 20
“Numerous recent papers have shown that PARP inhibitors and BRCA mutations not only induce neoantigens but also activate independent mechanisms improving the immune response to the tumour [46,141 – 145] ( ▶ Fig.”
Kyo, S., Kanno, K., Takakura, M., Yamashita, H., Ishikawa, M., Ishibashi, T., Sato, S., & Nakayama, K. (2022) · Cancers · doi:10.3390/cancers14102504 · Cited by 22
DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies
Dariane, C., & Timsit, M. (2022) · European Surgical Research · doi:10.1159/000526415 · Cited by 19
STING Targeting in Lung Diseases
Rodrigues, D. D. M., Lacerda‐Queiroz, N., Couillin, I., & Riteau, N. (2022) · Cells · doi:10.3390/cells11213483 · Cited by 20
Targeting the stimulator of interferon genes (STING) in breast cancer
Ying-rui, M., Bu-Fan, B., Deng, L., Rong, S., & Zhou, Q. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1199152 · Cited by 18
“Blocking DNA replication and repair affects genome integrity and activates the cGAS-STING signalling cascade (Chabanon et al., 2019).”
BackgroundWang, S., Zheng, Q.-Y., Hong, W.-F., Tang, B., Hsu, S.-J., Zhang, Y., Zheng, X., Zeng, Z.-C., Gao, C., Ke, A., et al. (2024) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2024.110424 · Cited by 17
Khaddour, K., Ansstas, M., Visconti, J., & Ansstas, G. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.602 · Cited by 17
Immunofluorescence microscopy-based assessment of cytosolic DNA accumulation in mammalian cells
Sato, A., Buqué, A., Yamazaki, T., Bloy, N., Petroni, G., & Galluzzi, L. (2021) · STAR Protocols · doi:10.1016/j.xpro.2021.100488 · Cited by 17
“The latter include irradiation (Rodriguez-Ruiz et al., 2019; Yamazaki et al., 2020) as well as a variety of pharmacological agents that interfere with DNA repair, such as poly(ADP-ribose) polymerase 1 (PARP1) (Chabanon et al., 2019; Ding et al., 2018) and ATR serine/threonine kinase (ATR) inhibitors (Dillon et al., 20…”
BackgroundcGAS-STING Pathway as the Target of Immunotherapy for Lung Cancer
Ge, H., Dan, Q., & Yang, Y. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009623666221115095114 · Cited by 19
“Some residual expression of ERCC1 is usually retained in NSCLC [43].”
BackgroundGenome instability and crosstalk with the immune response
Chabanon, R. M., Danlos, F. X., Ouali, K., & Postel-Vinay, S. C. (2025) · Genome Medicine · doi:10.1186/s13073-025-01509-6 · Cited by 21
“Activation of the cGAS-STING pathway has further been described in tumours undergoing DNA damage caused by endogenous DDR defects [15, 41, 48, 64, 227–233], a phenotype that was linked to increased TILs, notably in the context of HRR and NER defects [15, 31, 41], suggesting that cGAS-STING-driven…”
InfluentialSelf-citationXie, D., Jiang, B., Wang, S., Wang, Q., & Wu, G. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1200466 · Cited by 18
“The phosphorylation levels of the downstream effectors TBK1 and IRF3 were increased simultaneously (Chabanon et al., 2019; Zhang et al., 2022a).”
BackgroundLewicky, J. D., Martel, A. L., Gupta, M. R., Roy, R., Rodriguez, G. M., Vanderhyden, B. C., & Le, H. (2023) · Cancers · doi:10.3390/cancers15164127 · Cited by 17
“demonstrated that cytotoxic doses of the PARPis olaparib and rucaparib induced DNA damage and cGAS-STING-dependent type I IFN signaling in both a BRCA1-deficient TNBC cell line, and lung cancer cells lacking the excision repair crosscomplementation groups 1 (ERCC1) protein, a common DDR defect in non-small-cell lung c…”
BackgroundInfluentialResistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer
Li, L., Pu, H., Zhang, X., Guo, X., Li, G., & Zhang, M. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104683 · Cited by 17
Bailey‐Whyte, M., & Ambs, S. (2021) · Cancers · doi:10.3390/cancers13122874 · Cited by 17
“It has been suggested that enhancement of this genomic instability through use of radiation, chemotherapy, or PARP inhibitors could augment the immunotherapeutic response [114,120,121].”
BackgroundUnderstanding genetic determinants of resistance to immune checkpoint blockers
Aspeslagh, S., Chabanon, R. M., Champiat, S., & Postel-Vinay, S. C. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.020 · Cited by 17
Self-citationTherapeutic Application of PARP Inhibitors in Neuro-Oncology
Ning, J., & Wakimoto, H. (2020) · Trends in cancer · doi:10.1016/j.trecan.2019.12.004 · Cited by 17
PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers
Teyssonneau, D., Thiery-Vuillemin, A., Dariane, C., Barret, É., Beauval, J., Brureau, L., Créhange, G., Fiard, G., Fromont, G., Gauthé, M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061734 · Cited by 17
“PARPis can act as immunomodulatory agents, inducing PD-L1 expression through interferon (INF) after the activation of the cGAS/STING pathway via the accumulation of unrepaired DNA fragments [68].”
BackgroundZhou, A. Y., Butt, O. H., Ansstas, M., Mauer, E. A., Khaddour, K., & Ansstas, G. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7102 · Cited by 15
Luo, Z., Wan, Z., Ren, P., Zhang, B., Huang, Y., West, R. E., Huang, H., Chen, Y., Nolin, T. D., Xie, W., et al. (2024) · Advanced Science · doi:10.1002/advs.202307940 · Cited by 18
Molecular regulatory network of PD-1/PD-L1 in non-small cell lung cancer
Lingling, Z., Liu, J., Li, W., Danli, Y., Jie, Z., Li, W., Pu, D., Lei, P., & Qinghua, Z. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.152852 · Cited by 19
Liu, X., Xing, H., & Liu, B. (2022) · PubMed · Cited by 20
Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
Jiang, Y., Zhao, J., Zhang, L., Tian, S., Yang, T., Wang, L., Zhao, M., Yang, Q. F., Wang, Y., & Yang, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00954 · Cited by 16
“Another two studies also confirmed that PARP inhibitors can involve in anticancer immunity (35, 36).”
BackgroundHeyza, J. R., Ekinci, E., Lindquist, J., Lei, W. H., Yunker, C. K., Vinothkumar, V., Rowbotham, R., Polin, L., Snider-Hoy, N. G., Buren, E. C. V., et al. (2023) · NAR Cancer · doi:10.1093/narcan/zcac045 · Cited by 16
“In that context, increased micronuclei formation was associated with increased membranous PDL1 expression, activation of interferon signaling mediated by cGAS-STING, and secretion of CCL5 (39).”
Background
Metadata
- Authors
- Chabanon, R. M., Muirhead, G., Krastev, D. B., Adam, J., Morel, D., Garrido, M., Lamb, A., Hénon, C., Dorvault, N., Rouanne, M., Marlow, R., Bajrami, I., Cardeñosa, M. L., Konde, A., Besse, B., Ashworth, A., Pettitt, S. J., Haider, S., Marabelle, A., Tutt, A. N. J., Soria, J.-C., Lord, C. J., & Postel-Vinay, S.
- Affiliations
- Université Paris-Sud (FR)
- Breast Cancer Now (GB)
- Institute of Cancer Research (GB)
- Inserm (FR)
- Sage Bionetworks (US)
- King's College London (GB)
- University of California, San Francisco (US)
- ORCID
- Chabanon, Roman M.
- Krastev, Dragomir B.
- Adam, Julien
- Morel, Daphné
- Garrido, Marlène
- Lamb, Andrew
- Dorvault, Nicolas
- Rouanne, Mathieu
- Marlow, Rebecca
- Bajrami, Ilirjana
- Besse, Benjamin
- Ashworth, Alan
- Pettitt, Stephen J.
- Haider, Syed
- Marabelle, Aurélien
- Tutt, Andrew N.J.
- Soria, Jean-Charles
- Lord, Christopher J.
- Postel-Vinay, Sophie
- Venue
- Journal of Clinical Investigation
- Published
- 2019-02-11
- Volume
- 129
- Issue
- 3
- Pages
- 1211-1228
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6391116
- OpenAlex
- W2908418801
- Cited by
- 332
- References
- 62
- Citations by year
- 2026: 31 · 2025: 36 · 2024: 39 · 2023: 45 · 2022: 43 · 2021: 61 · 2020: 54 · 2019: 22
- FWCI
- 12.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- AstraZeneca
- Sanofi
- Merck KGaA
- Les Laboratories Pierre Fabre
- Fondation Philanthropia
- Cancer Research UK (14276, 25237, 24439)
- Institut National de la Santé et de la Recherche Médicale (INCa-DGOS-INSERM_12551)
- Institut National Du Cancer (INCa-DGOS-INSERM-12551)
- Institut Gustave-Roussy
- Direction Générale de l’offre de Soins
- Servier
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- PARP inhibitors, non-small cell lung cancer, triple-negative breast cancer, cGAS-STING pathway, cytosolic DNA sensing, type I interferon, PARP1, micronuclei, RANTES, PD-L1 expression, lymphocyte infiltration, olaparib, rucaparib, DNA repair deficiency
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Poly (ADP-Ribose) Polymerase-1, A549 Cells, STING Protein, Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase, Carcinoma, Non-Small-Cell Lung, DNA-Binding Proteins, Endonucleases, Female, Humans, Interferon-gamma, Lung Neoplasms, Membrane Proteins, Nucleotidyltransferases, BRCA1 Protein, B7-H1 Antigen, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.